Mr. Chair, I'll start again.
Merck's application for authorization for the antiviral drug molnupiravir is under review. Health Canada's regulatory team is using data from Merck's clinical trials to assess the benefits and risks of this product.
Deputy Minister, Department of Health
Mr. Chair, I'll start again.
Merck's application for authorization for the antiviral drug molnupiravir is under review. Health Canada's regulatory team is using data from Merck's clinical trials to assess the benefits and risks of this product.
See context to find out what was said next.